-
Mashup Score: 0Help me Challenge Cancer! - 4 hour(s) ago
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your support, we are saving more lives. #OneTeamOneFight
Source: dolphinscancerchallenge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Dr. Jashodeep Datta Recognized with Prestigious Award from the American College of Surgeons - InventUM - 25 day(s) ago
Dr. Datta is the first member of the Miller School to receive the Joan L. and Julius H. Jacobson II Promising Investigator Award.
Source: news.med.miami.eduCategories: General Medicine News, Oncologists1Tweet-
Thx to @umiamimedicine @LauraCastroComm for amplifying this: https://t.co/tAOZp2wVzI CC: @AcademicSurgery @UnivSurg @AsianAcadSurg @PanCAN @letswinpc @SocSurgOnc @AHPBA @IHPBA #pancsm
-
-
Mashup Score: 23
Abstract. Purpose: Interleukin (IL)-1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL-1 receptor accessory protein (IL1RAP)-targeting antibody with enhanced antibody-dependent cellular cytotoxicity that blocks IL-1α/IL-1β signaling. We investigated efficacy and safety of nadunolimab in PDAC, in combination with gemcitabine/nab-paclitaxel (GN). Patients and methods: Patients with previously untreated locally advanced/metastatic PDAC received nadunolimab (1.0-7.5 mg/kg) every two weeks with standard GN. The primary objective was safety; secondary objectives were anti-tumor response, progression-free survival (PFS) and overall survival (OS). Correlations between serum and tumor biomarkers and clinical response were explored. Results: 76 patients were enrolled, median age 63 years (range 43–89), 42% female, 97% with metastatic disease, 9% having received adjuvant chemotherapy. The most frequen
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Exciting Ph2 data in 1L mPDAC from Cantargia AB combining IL1RAP inh nadunolimab w/ gem/abraxane, published @CCR_AACR. N.B➡️naduno was to be next arm in @PanCAN #PrecisionPromise until FDA raised concerns abt dosing since initial trial was done in Europe https://t.co/VE4J1XvTlR
-
-
Mashup Score: 33
Background In patients with localized pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant therapy (NAT) and resection, selection of adjuvant chemotherapy (AC) is typically guided by high-…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
🚨New📄from @SylvesterCancer🫱🏽🫲🏾#CentralPancreasConsortium!How should we use pathologic lymph node metrics AFTER neoadjuvant tx &🔪in #PancreaticCancer pts➡️to guide adjuvant tx selection?Is LN➕/⛔️vity enough or LN ratio useful?Find out👉🏽https://t.co/4Fjgu3b9Rw @JofSurgOnc #pancsm https://t.co/JQ7WFYPZKi
-
-
Mashup Score: 23Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer - 4 month(s) ago
PURPOSE Using a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct molecular correlates underlying clinical differences between patients with young-onset pancreatic cancer (YOPC; younger than 50 years) and patients with average-onset pancreatic cancer (AOPC; 70 years and older). METHODS We analyzed matched whole-transcriptome and DNA sequencing data from 2,430 patient samples (YOPC, n = 292; AOPC, n = 2,138) from the Caris Life Sciences database (Phoenix, AZ). Immune deconvolution was performed using the quanTIseq pipeline. Overall survival (OS) data were obtained from insurance claims (n = 4,928); Kaplan-Meier estimates were calculated for age- and molecularly defined cohorts. Significance was determined as FDR-corrected P values (Q) < .05. RESULTS Patients with YOPC had higher proportions of mismatch repair–deficient/microsatellite instability-high, BRCA2-mutant, and PALB2-mutant tumors compared with patients with AOPC, but
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
📈in early onset GI cancers esp colorectal & pancreatic is of grave concern👇🏽#GI24. An opportunity to🔌our recent manuscript detailing the distinct molecular landscape of young onset #PancreaticCancer in @JCOPO_ASCO➡️https://t.co/iWxdnWBGcQ. Read🧵here: https://t.co/WWEoiq70F4 https://t.co/GnjGlpFAxq
-
-
Mashup Score: 37Post-Doctoral Associate - 4 month(s) ago
Current Employees: If you are a current Staff, Faculty or Temporary employee at the University of Miami, please click here to log in to Workday to use the internal application process. To learn how to apply for a faculty or staff position using the Career worklet, please review this tip sheet. The SCCC department is seeking a Postdoc Associate. The Postdoc Associate will conduct research on specific areas of study as assigned. Prepares research reports and technical papers for publishing. Investigates the feasibility of applying a wide variety of scientific principles and theories. Maintains substantial knowledge of state-of-the-art principles and theories. Develops advanced analytical models and systems and provides solutions and analyses to support strategic and tactical decisions. Adheres to University and unit-level policies and procedures and safeguards University assets. This list of duties and responsibilities is not intended to be all-inclusive and may be expanded to include ot
Source: umiami.wd1.myworkdayjobs.comCategories: General Medicine News, Hem/OncsTweet-
🚨JOB alert! Interested in #HomologousRecombinationDeficiency (eg BRCA1/2), STING signaling, type 1 interferon-induced immunity, or #PancreaticCancer #pancsm? @PeterHoseinMD & I are hiring @SylvesterCancer. Come join us in☀️Miami! Spread the word, & apply: https://t.co/P8fFbDRI4U https://t.co/no9moYK3KK
-
-
Mashup Score: 26Honoring Her ‘Angel’ - University of Miami Medicine Magazine - 4 month(s) ago
After an attempted surgery at a South Florida community hospital, doctors diagnosed Kathleen Garafola with locally advanced, unresectable pancreatic cancer.
Source: magazine.med.miami.eduCategories: General Medicine News, Hem/OncsTweet-
The bravery of our pts never ceases to amaze me. This enduring gift to our mission of eradicating #PancreaticCancer will remain a timeless testament to Kathy’s unflinching strength, & a💉in💪🏽 for our prgm @SylvesterCancer: https://t.co/RDe4K4SXwh CC: @noah_youngstrom @BrittenKing
-
-
Mashup Score: 22
Sylvester researchers are testing a new treatment approach for a subset of patients with pancreatic cancer.
Source: news.med.miami.eduCategories: General Medicine News, Hem/OncsTweet-
💪🏽🙏🏽🫶🏽. CC: @PeterHoseinMD Appreciate the support from @TheVFoundation @MiamiDolphins @TackleCancer @SylvesterCancer @DrSDNimer Read the story here: https://t.co/scbApGA2bf https://t.co/LVVVAQYMXH
-
-
Mashup Score: 3
Pancreatic ductal adenocarcinoma (PDAC) is characterized by intratumoral abundance of neutrophilic/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) which inhibit T-cell function through JAK2/STAT3-regulated arginase activity. To overcome limitations of systemic inhibition of PMN-MDSCs in cancer-bearing patients—i.e., neutropenia and compensatory myelopoietic adaptations—we develop a nanoengineering strategy to target cell-specific signaling exclusively in PMN-MDSCs without provoking neutropenia. We conjugate a chemically modified small-molecule inhibitor of MDSC-surface receptor CXCR2 (AZD5069) with polyethylene glycol (PEG) and chemically graft AZD5069-PEG constructs onto amphiphilic polysaccharide derivatives to engineer CXCR2-homing nanoparticles (CXCR2-NP). Cy5.5 dye-loaded CXCR2-NP showed near-exclusive uptake in PMN-MDSCs compared with PDAC tumor-cells, cancer-associated fibroblasts, and macrophages. Encapsulation of JAK2/STAT3i Ruxolitinib (CXCR2-NPRuxo) resulted in
Source: www.biorxiv.orgCategories: General Medicine News, Oncologists1Tweet-
Here is the link to this @DeptofDefense @CDMRP funded work: https://t.co/xazdpAghPf. 💪🏽💪🏽work by @iamnilesh1 driving this project & huge thx to @DharShanta for her expert guidance & collaboration
-
-
Mashup Score: 13
Annals of Surgical Oncology – Data regarding the survival impact of converting frozen-section (FS):R1 pancreatic neck margins to permanent section (PS):R0 by additional resection (i.e.,…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
Agreed! We published data with similar conclusions from the #CentralPancreasConsortium 7-center dataset a couple yrs ago @AnnSurgOncol👉🏽https://t.co/6N62mz3xET @SylvesterCancer @FrancisIgorMac1 @NbmerchantMD @SyedAAhmad5 @skmaithel @DavidKoobyMD @GregWilson152 @kimhjUNC et al https://t.co/EgZpu5GP3O
-
https://t.co/vv2gs2JLVe